Calls for papers
-
Approximately 400 OINDP experts gathered in Orlando, FL, USA May 1-May 5 for the first in-person Respiratory Drug Delivery meeting since 2019, with another 75 attending virtually. RDD Online’s Richard Dalby welcomed delegates from 28… Read more . . .
-
SoftOx Solutions has announced that a Phase 1 study of its SoftOx inhalation solution (SIS) demonstrated that nebulized SIS was well tolerated with no serious adverse effects observed and no adverse effects related to pulmonary… Read more . . .
-
According to Moderna Therapeutics, the company used its annual “Science and Technology Day” to highlight its work on lipid nanoparticle (LNP) mRNA formulations, and CEO Stéphane Bancel made special note of the company’s advances in… Read more . . .
-
Aston University spin out Aston Particle Technologies (APT) has closed a £1 million funding round according to lead investor DSW Ventures. The funding will be used for scale up of APT’s isothermal dry particle coating… Read more . . .
-
Sumitovant subsidiary Spirovant Sciences, which is developing inhaled gene therapies for the treatment of cystic fibrosis, has opened a new research laboratory and corporate headquarters in Philadelphia, PA, USA, the company said. Spirovant’s SP-101 inhaled adeno-associated… Read more . . .
-
Pneumagen has announced that a Phase 1 dose escalation study of its Neumifil carbohydrate binding module nasal spray demonstrated that the nasal spray was well tolerated and had no dose limiting toxicity. Pneumagen announced the… Read more . . .
-
According to Indian generics developer Alembic Pharmaceuticals, the company’s ANDA for a generic version of Sunovion’s Brovana arformoterol tartrate inhalation solution for the treatment of COPD has received final FDA approval. Alembic co-developed the arformoterol… Read more . . .
-
In a business update, Pieris Pharmaceuticals warned that an ongoing clinical trial of its dry powder PRS-060/AZD1402 IL-4 receptor alpha inhibitor may take longer than expected, saying “Given the geopolitical situation, along with broader challenges… Read more . . .
-
Scottish nebulizer developer Nebu-Flow has raised £1.7 million “to continue the commercialization and delivery of next generation respiratory pharmaceuticals,” the company has announced on social media. The funding round was led by Foresight Williams Technology.… Read more . . .
-
Zeteo Biomedical has announced the launch of its ZEOx1 OrionMRQ metered dose nasal device for delivery of drugs and vaccines. Zeteo’s ZEOx1 devices are designed for intranasal delivery of liquid formulations, and its ZEOx2 devices… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA